Mochida Pharmaceutical
As of the edition of 20 October 2026, Mochida Pharmaceutical runs 9 drugs, 8 of them marketed; it is on route A at 1 target and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Escitalopram | Ended 2026 (exclusivity) | 4 |
| Imiquimod | none listed | 2 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Treprostinil | Ends 2028 (patent) | 3 |
| Dienogest | none listed | 1 |
| Icosapent ethyl | none listed | 3 |
| Dotinurad | none listed | 1 |
| Icosapent | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 5 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Mochida Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 2 trials led
- Digestive system: 1 trials led